No Data
No Data
$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Express News | Diabetes Device Makers' Shares Down After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial
Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Barclays Names Most and Least Affected Healthcare Companies From Tariffs
RBC Capital Maintains Insulet(PODD.US) With Buy Rating, Cuts Target Price to $325
What's Driving the Market Sentiment Around Insulet?